Tzield Gets FDA Nod to Become First Approved Drug to Delay Onset of Type 1 Diabetes
XTalks
NOVEMBER 22, 2022
Provention Bio’s Tzield (teplizumab) has won US Food and Drug Administration (FDA) approval to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older who have stage 2 type 1 diabetes. In the US, it is estimated that 1.45 million people are currently living with type 1 diabetes.
Let's personalize your content